A Biology Modality MCP review of P2RY13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of P2RY12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of P2RY11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of P2RY10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of P2RY6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of NPR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of EBI3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

NCT07771530 clinical trial report covering Methylphenidate Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white spac

NCT07771855 clinical trial report covering Tezepelumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07771764 clinical trial report covering Pemetrexed Dipotassium, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

ChiCTR2600130265 clinical trial report covering Ipilimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.

NCT07774364 clinical trial report covering AT-004 (Arctic Therapeutics), Phase 2, endpoints, sponsor, geography, readout timing and development white space